Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00792025
Other study ID # CDR0000618219
Secondary ID FRE-CRH-06-374-M
Status Completed
Phase Phase 2
First received November 14, 2008
Last updated May 14, 2011
Start date December 2008

Study information

Verified date July 2009
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying sunitinib to see how well it works as second-line therapy in treating patients with locally advanced or metastatic transitional cell cancer.


Description:

OBJECTIVES:

Primary

- To determine the objective tumor response rate according to RECIST criteria in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium treated with sunitinib malate who failed or progressed after first-line chemotherapy .

Secondary

- To determine the safety of this drug.

- To determine the time to response and duration of response.

- To determine the progression-free survival and overall survival of these patients.

- To evaluate the quality of life of these patients.

OUTLINE: This is a multicenter study.

Patients receive oral sunitinib malate once daily for 4 weeks. Courses repeat every 6 weeks for 12 months in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed every 2 months.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed transitional cell cancer of the urothelium

- Advanced or metastatic disease

- Disease failed or progressed after first-line chemotherapy

- At least 1 non-irradiated measurable lesion assessed by CT scan or MRI according to RECIST

- No progressive brain metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- ANC = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 8g/dL

- Total bilirubin = 1.5 times upper limit of normal (ULN)

- AST and ALT = 2.5 times ULN (= 5 times ULN in presence of liver metastases)

- Creatinine clearance = 40 mL/min

- PTT and INR = 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during study treatment

- No uncontrolled high BP, defined as > 150/100 mm Hg despite treatment

- No diagnosis of a second malignancy within the past 5 years, except for basal cell or squamous cell carcinoma of the skin, incidental PT2 prostate cancer found on radical cystoprostatectomy material, or carcinoma in situ of the cervix, that has been adequately treated with no evidence of recurrence in the past 12 months

- None of the following within the past 12 months:

- Myocardial infarction

- Severe/unstable angina pectoris

- Coronary artery bypass graft

- Symptomatic congestive heart failure

- Cerebrovascular accident

- Transient ischemic attack

- Pulmonary embolism

- At least 6 months since deep vein thrombosis

- No NCI CTCAE grade 3 hemorrhage within the past 4 weeks

- No pre-existing neuropathy = NCI CTCAE grade 2

- No history of interstitial pneumonitis or pulmonary fibrosis

- No ongoing cardiac arrhythmias = NCI CTCAE grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval (> 450 msec for males or > 470 msec for females)

- No ongoing active infection

- No patients deprived of liberty or who are under supervision (including a trusteeship)

- No psychological, familial, sociological, or geographic condition potentially hampering compliance with study treatment and follow-up

- Patients must be affiliated to a social security system

PRIOR CONCURRENT THERAPY:

- Prior platinum-based therapy allowed

- No prior sunitinib malate

- No prior radiotherapy to = 25% of marrow producing area

- Prior neoadjuvant or adjuvant chemotherapy allowed

- More than 2 weeks since prior and no concurrent oral anticoagulant agents at therapeutic doses

- Low molecular weight heparin allowed

- At least 30 days since prior chemotherapy or radiotherapy and recovered

- No other concurrent anticancer treatment, including experimental agents, or participation in another investigational trial

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
sunitinib malate


Locations

Country Name City State
France Centre Rene Huguenin Saint Cloud
France Hopital Foch Suresnes

Sponsors (1)

Lead Sponsor Collaborator
Centre Rene Huguenin

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response as assessed by RECIST criteria No
Secondary Progression-free survival No
Secondary Overall survival No
Secondary Time to response and duration of response No
Secondary Safety Yes
Secondary Quality of life No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A